Education
About Us
Working with TipRanks
Follow Us
Passage Bio (PASG)
NASDAQ:PASG
PASG Stock Chart & Stats
$8.99
>-$0.01(-0.86%)
At close: 4:00 PM EST
$8.99
>-$0.01(-0.86%)
Day’s Range― - ―
52-Week Range$5.12 - $26.60
Previous CloseN/A
Volume182.24K
Average Volume (3M)41.18K
Market Cap
$24.14M
Enterprise Value-$2.91M
Total Cash (Recent Filing)$52.77M
Total Debt (Recent Filing)$24.34M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Mar 09, 2026EPS Estimate
-2.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.44
Shares Outstanding3,120,295
10 Day Avg. Volume55,130
30 Day Avg. Volume41,182
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.56
Price to Sales (P/S)0.00
P/FCF Ratio-0.71
Enterprise Value/Market Cap-0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.17
Enterprise Value/Ebitda0.07
Forecast
1Y Price Target
$40.33Price Target Upside348.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPassage Bio's latest Ph1/2 interim data showed treatment with PBFT02 produced strong CSF PGRN elevation and NfL stabilization, which support POM and target engagement in FTD-GRN patients.
Financial PerformanceThe end of 3Q25 total cash of $52.8M continues to support a runway into 1Q27, and clinical and regulatory updates in 1H26 are likely to be positive, providing strong catalysts for the stock.
Regulatory ApprovalFDA is expected to agree on a single-arm registrational study due to high unmet medical need in FTD and newly published guidelines on cell and gene therapy.
Bears Say
Safety ConcernsThe company also saw a fourth SAE (pulmonary embolism) in the first dose 2 patient, prompting the recent filing of an amended safety protocol.
Passage Bio News
PASG FAQ
What was Passage Bio’s price range in the past 12 months?
Passage Bio lowest stock price was $5.12 and its highest was $26.60 in the past 12 months.
What is Passage Bio’s market cap?
Passage Bio’s market cap is $24.14M.
When is Passage Bio’s upcoming earnings report date?
Passage Bio’s upcoming earnings report date is Mar 09, 2026 which is in 100 days.
How were Passage Bio’s earnings last quarter?
Passage Bio released its earnings results on Nov 18, 2025. The company reported -$2.44 earnings per share for the quarter, beating the consensus estimate of -$2.758 by $0.318.
Is Passage Bio overvalued?
According to Wall Street analysts Passage Bio’s price is currently Undervalued.
Does Passage Bio pay dividends?
Passage Bio does not currently pay dividends.
What is Passage Bio’s EPS estimate?
Passage Bio’s EPS estimate is -2.57.
How many shares outstanding does Passage Bio have?
Passage Bio has 3,120,295 shares outstanding.
What happened to Passage Bio’s price movement after its last earnings report?
Passage Bio reported an EPS of -$2.44 in its last earnings report, beating expectations of -$2.758. Following the earnings report the stock price went down -7.512%.
Which hedge fund is a major shareholder of Passage Bio?
Currently, no hedge funds are holding shares in PASG
Company Description
Passage Bio
Passage Bio (PASG) is a biotechnology company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders. The company specializes in gene therapies, utilizing cutting-edge technologies to address unmet medical needs in neurology. With a robust pipeline of therapies in various stages of development, Passage Bio aims to deliver precision medicine solutions to patients with debilitating genetic conditions.
PASG Stock 12 Month Forecast
Average Price Target
$40.33
▲(348.61% Upside)
Technical Analysis
Tempest Therapeutics
―
Chemomab Therapeutics
―
Annovis Bio
―
Generation Bio
―
Cognition Therapeutics
―
Ownership Overview
Currently, No data available
---